Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in <scp>C</scp>hinese patients with type 2 diabetes mellitus

Abstract

Acarbose treatment can increase the content of gut Bifidobacterium longum in type 2 diabetes mellitus patients and decrease some inflammatory cytokines independently of its antihyperglycemic effects.